BAD VILBEL, Germany and STOCKHOLM, Sept. 28, 2023 /PRNewswire/ -- Partners STADA and Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a request to the European Medicines Agency (EMA) for the Committee for Medicinal Products for Human Use (CHMP) to convert the conditional marketing authorization for Kinpeygo®, their treatment for primary IgA nephropathy (IgAN), to standard, or "full", marketing authorization.
Read more at prnewswire.comSTADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here